Evidence map›Paper›PMID 41411087›Full record

ArticleJournal of radiation research2026

Imaging dose in image-guided radiotherapy for localized prostate intensity-modulated radiotherapy: a nationwide survey in Japan.

Satoshi Kito, Takeshi Takizawa, Satoshi Tanabe, Yuhi Suda, Tomomasa Nagahata, Naoki Tohyama, Hiroyuki Okamoto, Takumi Kodama, Yukio Fujita, Hisayuki Miyashita and 5 more

Abstract read
In one paragraph

Article in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Satoshi KitoDivision of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677  Japan.ORCID 0000-0002-8360-5544
Takeshi TakizawaDepartment of Radiation Oncology, Niigata Neurosurgical Hospital, 3057 Yamada, Nishi-ku 950-1101  Japan.
Satoshi TanabeDepartment of Radiation Oncology, Niigata University Medical and Dental Hospital, 1-757 Asahimachi-dori, Chuo-ku 951-8510  Japan.ORCID 0000-0002-3488-3871
Yuhi SudaDivision of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677  Japan.
Tomomasa NagahataRadiological Division in Osaka Metropolitan University Hospital, 1-5-7 Asahi-chou, Osaka 545-8586  Japan.
Naoki TohyamaDepartment of Radiation Sciences, Komazawa University, 1-23-1 Komazawa, Setagaya, Tokyo 154-8525  Japan.
Hiroyuki OkamotoRadiation Safety and Quality Assurance Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku 104-0045  Japan.ORCID 0000-0001-9491-787X
Takumi KodamaDepartment of Radiation Oncology, Saitama Cancer Center, 780, Ooazakomuro, Ina 362-0806  Japan.
Yukio FujitaDepartment of Radiation Sciences, Komazawa University, 1-23-1 Komazawa, Setagaya, Tokyo 154-8525  Japan.
Hisayuki MiyashitaDepartment of Radiation Oncology, St. Marianna University Hospital, 2-16-1, Sugao, Miyamae-ku, Kawasaki-City, Kanagawa 216-8511  Japan.
Kazuya ShinodaDepartment of Radiation Therapy, Ibaraki Prefectural Central Hospital, 6528 Koibuchi, Kasama City, Ibaraki 309-1793  Japan.ORCID 0000-0002-8491-9799
Masahiko KurookaDepartment of Radiation Therapy, Tokyo Medical University Hospital, 6-7-1 Nishishinjuku, Shinjuku-ku 160-0023  Japan.
Hidetoshi ShimizuDivision of Medical Physics, School of Medical Sciences, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Aichi 470-1192  Japan.ORCID 0000-0002-6633-0964
Takeshi OhnoDepartment of Health Sciences, Faculty of Life Sciences, Kumamoto University, 4-24-1 Kuhonji, Chuo-ku, Kumamoto 862-0976  Japan.
Masataka SakamotoDepartment of Radiology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Higashi-ku, Hamamatsu, Shizuoka 431-3192  Japan.ORCID 0000-0003-2407-8622

Funding

JASTRO 2020-2021
6 · The paper itself

Abstract

This study aimed to establish the diagnostic reference levels (DRLs) of imaging doses for image-guided radiotherapy (IGRT) used in intensity-modulated radiotherapy for prostate cancer in Japan. A nationwide survey was conducted to gather data on image acquisition conditions, parameters, and frequencies across 193 radiation therapy institutions using intensity-modulated radiotherapy. IGRT modalities, such as kilovoltage and megavoltage cone-beam computed tomography (CBCT), two-dimensional imaging, and in-room computed tomography (CT), were targeted. Data analysis focused on image acquisition parameters displayed by the devices, such as tube voltage, current, and imaging dose, along with the CT dose index volume (CTDIvol) and dose-length product (DLP), were collected from 222 radiotherapy devices. The results showed that kV-CT/CBCT was the most frequently used modality, used in 94% of the institutions. Imaging dose-reduction techniques were adopted by over half of the institutions, with 56% optimizing imaging parameters and 45% reducing the imaging field size or scan length. The 75th percentile for CTDIvol was 16.0 mGy, while that for DLP was 263 mGy·cm, with considerable variation among devices and institutions. This study provides the first large-scale reference data for IGRT imaging doses used for prostate cancer treatment in Japan. These results are critical for improving patient safety by optimizing imaging protocols and establishing DRLs tailored to IGRT. These findings will serve as a basis for further refinement of radiological protection practices in Japan.

Indexed as

Prostatic NeoplasmsRadiation DosageRadiotherapy, Image-GuidedRadiotherapy, Intensity-ModulatedCone-Beam Computed TomographyHumansJapanMaleRadiotherapy DosageSurveys and QuestionnairesCTDIvoldiagnostic reference levelsDLPimage-guided radiotherapyprostate cancerradiological protection

Identifiers

PMID41411087
PMCPMC12856032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.